Carmot Therapeutics secures $160 million in Series D funding

Carmot Therapeutics is a clinical-stage innovative drug developer using its proprietary drug discovery platform, Chemotype Evolution, to discover and develop disease-modifying therapies for patients with metabolic diseases and cancer. Carmot Therapeutics announced the completion of a US$160 million Series D financing led by The Column Group, followed by RA Capital to invest a considerable share, and institutional investors such as Deep Track Capital, Willett Advisors, Horizons Ventures (Haigang Investment) also participated. This round of financing. In addition, RA Capital will receive a board observer seat at Carmot.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.